Rep. Maria Elvira Salazar Sells Moderna, Inc. (NASDAQ:MRNA) Stock

Key Points

• Rep. Maria Elvira Salazar sold $1,001–$15,000 of Moderna stock on August 19 from her UBS brokerage account; she also reported purchasing the same dollar range of Moderna shares that day.
• Moderna shares opened at $136.62, well above their 50-day average of $91.07 and 200-day average of $66.19. The company recently beat quarterly revenue and EPS expectations but remains unprofitable.
• Institutional ownership stands at 75.33%, with major additions from BlackRock and California State Teachers’ Retirement System. Analysts maintain a consensus “Hold” rating with an average price target of $76.72.

Representative Maria Elvira Salazar (Republican-Florida) recently sold shares of Moderna, Inc. NASDAQ: MRNA. In a filing disclosed on September 09th, the Representative disclosed that they had sold between $1,001 and $15,000 in Moderna stock on August 19th. The trade occurred in the Representative's "UBS BROKERAGE ACCOUNT" account.

Representative Maria Elvira Salazar also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of International Business Machines NYSE: IBM on 8/24/2026.
• Purchased $1,001 - $15,000 in shares of Moderna NASDAQ: MRNA on 8/19/2026.
• Sold $1,001 - $15,000 in shares of Qualcomm NASDAQ: QCOM on 8/19/2026.
• Purchased $15,001 - $50,000 in shares of Merck & Co., Inc. NYSE: MRK on 8/19/2026.
• Sold $15,001 - $50,000 in shares of Chubb NYSE: CB on 8/19/2026.
• Sold $1,001 - $15,000 in shares of Qualcomm NASDAQ: QCOM on 8/12/2026.
• Purchased $1,001 - $15,000 in shares of SpaceX NASDAQ: SPCX on 8/12/2026.
• Purchased $1,001 - $15,000 in shares of Berkshire Hathaway NYSE: BRK.B on 8/7/2026.
• Purchased $1,001 - $15,000 in shares of Berkshire Hathaway NYSE: BRK.B on 7/28/2026.
• Purchased $15,001 - $50,000 in shares of Berkshire Hathaway NYSE: BRK.B on 7/28/2026.

Moderna Stock Performance

NASDAQ MRNA opened at $136.62 on Friday. The stock has a fifty day simple moving average of $91.07 and a 200-day simple moving average of $66.19. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. The stock has a market cap of $54.54 billion, a PE ratio of -17.10 and a beta of 1.10. Moderna, Inc. has a twelve month low of $22.28 and a twelve month high of $176.66.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings data on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The firm had revenue of $145.00 million for the quarter, compared to analyst estimates of $102.93 million. During the same period in the previous year, the firm earned ($2.13) EPS. Moderna's revenue was up 2.1% on a year-over-year basis. Equities analysts anticipate that Moderna, Inc. will post -6.09 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in MRNA. BlackRock Inc. purchased a new position in Moderna in the second quarter valued at $2,142,877,000. California State Teachers Retirement System increased its holdings in Moderna by 6,698.1% during the 2nd quarter. California State Teachers Retirement System now owns 27,681,318 shares of the company's stock worth $1,938,523,000 after purchasing an additional 27,274,128 shares during the period. Capital World Investors acquired a new stake in Moderna in the 4th quarter valued at about $378,299,000. Theleme Partners LLP acquired a new stake in Moderna in the 2nd quarter valued at about $564,272,000. Finally, Alyeska Investment Group L.P. acquired a new stake in Moderna in the 4th quarter valued at about $95,209,000. Institutional investors and hedge funds own 75.33% of the company's stock.

Insider Activity

In other news, insider Shannon Klinger sold 3,471 shares of the business's stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total transaction of $485,766.45. Following the completion of the transaction, the insider directly owned 74,129 shares of the company's stock, valued at approximately $10,374,353.55. The trade was a 4.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 53,336 shares of the company's stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the sale, the president owned 1,483,848 shares in the company, valued at $76,225,271.76. The trade was a 3.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 10.80% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on MRNA. UBS Group set a $81.00 price target on shares of Moderna in a research note on Thursday, September 3rd. Morgan Stanley increased their price objective on shares of Moderna from $39.00 to $89.00 and gave the stock an "equal weight" rating in a research report on Thursday, August 20th. Bank of America upgraded shares of Moderna from an "underperform" rating to a "neutral" rating in a report on Wednesday, August 19th. Wolfe Research raised Moderna from an "underperform" rating to a "peer perform" rating in a research report on Tuesday, August 25th. Finally, CLSA upgraded Moderna to an "outperform" rating in a research note on Friday, August 28th. Seven analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and five have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Moderna has an average rating of "Hold" and an average target price of $76.72.

About Representative Salazar

Maria Elvira Salazar (Republican Party) is a member of the U.S. House, representing Florida's 27th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027. Salazar (Republican Party) ran for re-election to the U.S. House to represent Florida's 27th Congressional District. She won in the general election on November 5, 2024. Maria Elvira Salazar was born in Miami, Florida, and lives in Coral Gables, Florida. Salazar earned an undergraduate degree from the University of Miami in 1983 and a graduate degree from Harvard University in 1995. Her career experience includes working as a television journalist, reporter, and news anchor.

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops messenger RNA (mRNA) medicines and vaccines. Its platform is designed to provide cells with instructions to produce proteins that may help prevent or treat infectious diseases, cancer and other medical conditions.

The company's commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults. Moderna also maintains a pipeline of investigational programs in areas such as seasonal influenza, cytomegalovirus, oncology and rare diseases.

Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna serves markets in the United States and internationally through regulatory approvals, commercial partnerships and distribution arrangements.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.